Trial Profile

A Double Blind, Randomized, Placebo-Controlled, Multicenter Phase IIa, Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab in IgA Nephropathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Felzartamab (Primary)
Indications IgA nephropathy
Focus Proof of concept; Therapeutic Use
Acronyms IGNAZ
Sponsors Biogen; Human Immunology Biosciences; MorphoSys

Most Recent Events

03 Jun 2026 According to a Biogen media release, data from this trial will be presented at the 63rd European Renal Association Congress (ERA) and the 2026 American Transplant Congress (ATC).
03 Nov 2025 According to a Biogen media release, the data from the trial will be presented at Kidney Week 2025, the American Society of Nephrology's (ASN) annual meeting
01 Oct 2025 Results published in the Kidney International

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com